Dimopoulos Highlights Benefit of Elotuzumab Triplet in Relapsed/Refractory Myeloma
July 2nd 2019Meletios A. Dimopoulos, MD, discusses where the triplet combination of elotuzumab (Empliciti), pomalidomide (Pomalyst), and low-dose dexamethasone fits into the treatment paradigm of relapsed/refractory multiple myeloma and shared unanswered questions that remain in the space.
Read More
Avelumab/Axitinib Combo Biomarker Analysis May Lend Insight to Complex RCC Landscape
June 11th 2019Toni Choueiri, MD, discusses the biomarker analysis results from JAVELIN Renal 101 and provided insight on where the renal cell carcinoma field stands following pivotal data presented at the 2019 ASCO Annual Meeting.
Read More